Assessment of the role of circulating breast cancer cells in tumor formation and metastatic potential using in vivo flow cytometry

Hwu, Derrick; Boutrus, Steven; Greiner, Cherry; DiMeo, Theresa; Kuperwasser, Charlotte; Georgakoudi, Irene

doi:doi:10.1117/1.3560624

GENERAL INFORMATION

Journal of Biomedical Optics / Volume 16 / Issue 4 / JBO Letters

J. Biomed. Opt. 16, 040501 (Apr 01, 2011); http://dx.doi.org/10.1117/1.3560624

Alerts
- Alert Me When Cited
- Alert Me When Corrected
Tools
Share
- Email Abstract
- Connotea
- CiteULike
- del.icio.us
- BibSonomy
- Tweet this Article
- Add to Facebook

Abstract

References (12)

Citing Articles (2)

Derrick Hwu, Steven Boutrus, Cherry Greiner, and Irene Georgakoudi

Tufts University, Department of Biomedical Engineering, 4 Colby Street, Medford, Massachusetts 02155

Theresa DiMeo and Charlotte Kuperwasser

Tufts University School of Medicine, Department of Anatomy and Cellular Biology, Boston, Massachusetts 02111

The identification of breast cancer patients who will ultimately progress to metastatic disease is of significant clinical importance. The quantification and assessment of circulating tumor cells (CTCs) has been proposed as one strategy to monitor treatment effectiveness and disease prognosis. However, CTCs have been an elusive population of cells to study because of their small number and difficulties associated with isolation protocols. In vivo flow cytometry (IVFC) can overcome these limitations and provide insights in the role these cells play during primary and metastatic tumor growth. In this study, we used two-color IVFC to examine, for up to ten weeks following orthotopic implantation, changes in the number of circulating human breast cells expressing GFP and a population of circulating hematopoietic cells with strong autofluorescence. We found that the number of detected CTCs in combination with the number of red autofluorescent cells (650 to 690 nm) during the first seven days following implantation was predictive in development of tumor formation and metastasis eight weeks later. These results suggest that the combined detection of these two cell populations could offer a novel approach in the monitoring and prognosis of breast cancer progression, which in turn could aid significantly in their effective treatment.

History

Received Dec 13, 2010
Accepted Feb 10, 2011
Revised Feb 01, 2011
Published online Apr 01, 2011

Digital Object Identifier

http://dx.doi.org/10.1117/1.3560624

Citation

Derrick Hwu, Steven Boutrus, Cherry Greiner, Theresa DiMeo, Charlotte Kuperwasser and Irene Georgakoudi, "Assessment of the role of circulating breast cancer cells in tumor formation and metastatic potential using in vivo flow cytometry", J. Biomed. Opt. 16, 040501 (Apr 01, 2011); http://dx.doi.org/10.1117/1.3560624

DOWNLOAD ARTICLE

OPEN ACCESS

FULL-TEXT OPTIONS:

Read Online (HTML)
Download PDF

RELATED CONTENT

More Like This Article | Related Patents

More Like This Article

View in Separate Window/Tab pop up window icon

Selected: Export Citations | Add to MyArticles

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, and M. J. Thun, “Cancer statistics, 2008,” CA Cancer J. Clin. 58(2), 71–96 (2008). [MEDLINE]
M. Cristofanilli, G. Budd, M. Ellis, A. Stopeck, J. Matera, M. Miller, J. Reuben, G. Doyle, W. Allard, L. Terstappen, and D. Hayes, “Circulating tumor cells, disease progression, and survival in metastatic breast cancer,” N. Engl. J. Med. 351(8), 781–791 (2004). [MEDLINE]
A. L. Allan, S. A. Vantyghem, A. B. Tuck, A. F. Chambers, I. H. Chin-Yee, and M. Keeney, “Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry,” Cytometry A 65(1), 4–14 (2005).
S. Nagrath, L. Sequist, S. Maheswaran, D. Bell, D. Irimia, L. Ulkus, M. Smith, E. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. Balis, R. Tompkins, D. Haber, and M. Toner, “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” Nature 450, 1235–1239 (2007).
J. Novak, I. Georgakoudi, X. Wei, A. Prossin and C. P. Lin, “In vivo flow cytometer for real-time detection and quantification of circulating cells,” Opt. Lett. 29(1), 77–79 (2004). [ISI] [MEDLINE]
S. Boutrus, C. Greiner, D. Hwu, M. Chan, C. Kuperwasser, C. P. Lin, and I. Georgakoudi, “Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labeled circulating cells,” J. Biomed. Opt. 12(2), 020507 (2007)JBOPFO000012000002020507000001. [MEDLINE]
D. A. Sipkins, X. Wei, J. W. Wu, J. M. Runnels, D. Cote, T. K. Means, A. D. Luster, D. T. Scadden, and C. P. Lin, “In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment,” Nature 435(7044), 969–973 (2005). [MEDLINE]
W. He, H. Wang, L. C. Hartmann, J. X. Cheng, and P. S. Low, “In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry,” Proc. Natl. Acad. Sci. USA 104(28), 11760–11765 (2007). [MEDLINE]
E. R. Tkaczyk, A. H. Tkaczyk, S. Katnik, J. Y. Ye, K. E. Luker, G. D. Luker, A. Myc, J. R. Baker, Jr., and T. B. Norris, “Extended cavity laser enhanced two-photon flow cytometry,” J. Biomed. Opt. 13(4), 041319 (2008)JBOPFO000013000004041319000001. [MEDLINE]
I. Georgakoudi, N. Solban, J. Novak, W. L. Rice, X. Wei, T. Hasan, and C. P. Lin, “In vivo flow cytometry: A new method for enumerating circulating cancer cells,” Cancer Research 64, 5044–5047 (2004). [ISI] [MEDLINE]
J. P. Shaw, R. Basch, and P. Shamamian, “Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45,” Blood Cells Mol. Dis. 32(1), 168–175 (2004).
S. B. Bradfute, T. A. Graubert, and M. A. Goodell, “Roles of Sca-1 in hematopoietic stem/progenitor cell function,” Exp. Hematol. 33(7), 836–843 (2005).